4//SEC Filing
Bencich John 4
Accession 0000950170-24-027243
CIK 0000949858other
Filed
Mar 5, 7:00 PM ET
Accepted
Mar 6, 4:43 PM ET
Size
7.8 KB
Accession
0000950170-24-027243
Insider Transaction Report
Form 4
Bencich John
CFO and PFO
Transactions
- Purchase
Common Stock
2024-03-04$4.58/sh+10,000$45,850→ 76,724 total - Purchase
Common Stock Warrants (right to buy)
2024-03-04+10,000→ 10,000 totalExercise: $4.91From: 2024-03-04→ Common Stock (10,000 underlying)
Footnotes (2)
- [F1]The common shares reported on this Form 4 were purchased in a registered direct offering (the "RDO") at a price of $4.585, for an aggregate purchase price of $45,850 pursuant to a Securities Purchase Agreement (the "SPA") dated February 28, 2024. The SPA also provides for a concurrent private placement of warrants to purchase common shares (the "Private Placement Warrants") . The Private Placement Warrants are exercisable immediately upon issuance until the earlier of (x) three and one-half years after the date of issuance, and (y) 30 days following the Issuer's public disclosure of the acceptance of an NDA for cytisinicline by the FDA in a Day 74 Letter or equivalent correspondence.
- [F2]This number reflects a decrease of ownership of 6 shares of common stock from the number of shares previously reported due to an administrative error at the time of the Issuer's 1-for-20 split on July 31, 2020.
Documents
Issuer
ACHIEVE LIFE SCIENCES, INC.
CIK 0000949858
Entity typeother
Related Parties
1- filerCIK 0001477056
Filing Metadata
- Form type
- 4
- Filed
- Mar 5, 7:00 PM ET
- Accepted
- Mar 6, 4:43 PM ET
- Size
- 7.8 KB